OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Cogstate Ltd. (ASX: CGS;OTCQX: COGZF), a cognitive science and technology company publicly listed on the Australian Securities Exchange, has qualified to trade on the OTCQX® Best Market. Cogstate Ltd. upgraded to OTCQX from the Pink® market.
ERT Announced Partnership with Cogstate to Expand its eCOA Solution for Higher Fidelity CNS Assessments
ERT, the global leader in clinical endpoint data collection, today announced a preferred partnership with Cogstate to expand its industry-leading electronic Clinical Outcome Assessment (eCOA) solution with digital cognitive endpoints from Cogstate to support the development of treatments for Central Nervous System (CNS) and other disorders.
Cogstate Receives Digital Biomarker Award from ADDF to Develop Mobile App for Early Detection of Memory Impairment
Cogstate today announced an award from the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) initiative, which is a partnership of funders seeking to develop novel biomarkers for the early detection of Alzheimer’s disease and related dementias. The up to $1.3 million award to Cogstate will be focused on the development of a technology-based approach for early detection of memory impairment and decline.
Eisai Co., Ltd (Tokyo) today announced the launch of “NouKNOW”, a digital tool for self-assessment of brain health based upon technology created by Cogstate. The Japanese product launch will occur on 31 March 2020 and will initially target municipalities providing health services to local residents and corporations providing health checks for employees.
Cogstate announced today that Ken Billard has joined the company in the role of Chief Commercial Officer. Ken brings proven expertise in sales leadership and strategic partnering to Cogstate, where he will oversee the global sales organization to develop and execute strategies focused on expanding the adoption of Cogstate solutions in pharmaceutical clinical trials.
Eisai Enters Into Business Alliance with Cogstate for Exclusive Development and Commercialization of a Digital Tool for Self-Assessment of Cognitive Function in Japan
Eisai entered into a business alliance agreement with Cogstate for exclusive development and commercialization of a cognitive function test, the Cogstate Brief Battery (CBB), in Japan as a digital tool for self-assessment of cognitive function.
Cogstate today announced a presentation entitled, “Methodology for Development of Indication-Specific Outcome Measures in Rare Disease Trials: An Innovative Research Approach” will be delivered at the National Organization for Rare Diseases (NORD) Rare Disease Summit in Washington, D.C.
Cogstate, today announced that its Healthcare Division has received CE Mark approval for its Cognigram™ digital cognitive assessment system.
A new research framework for understanding Alzheimer’s disease has been developed and released by the Alzheimer’s Association (AA) and the National Institute on Aging (NIA).
Cogstate today announced the establishment of a Rare Disease and Pediatric Center of Excellence to lead all activities related to the selection and administration of cognitive and behavioral outcome measures in rare disease and pediatric clinical trials.